Show simple item record

dc.creatorKoshak, Abdulrahman E.
dc.creatorKoshak, Emad A.
dc.date.accessioned2020-08-26T14:49:18Z
dc.date.available2020-08-26T14:49:18Z
dc.date.created2020
dc.identifier.issn0011-393Xspa
dc.identifier.otherhttps://doi.org/10.1016/j.curtheres.2020.100602spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/12300
dc.description.abstractBackground Coronaviruses are responsible for several human diseases such as the pandemic infectious disease 2019 (COVID-19) which is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Nigella sativa (NS) is a natural food supplement with a known safety profile that may provide a wealth of known antiviral compounds. Objective To explore the studies supporting the NS potential for hitting SARS-CoV-2 targets. Methods A literature search for scientific published or preprint in-silico studies between 1990 and 2020 in electronic databases (PubMed, Science Direct, Scopus, and Google Scholar) was performed for the terms Nigella sativa, black seed, coronavirus, SARS-CoV-2 and COVID-19. Results At least eight in-silico studies have shown that some compounds of NS, including Nigelledine, α-Hederin, Hederagenin, Thymohydroquinone, and Thymoquinone, had high to moderate affinity with SARS-CoV-2 enzymes and proteins. These compounds may potentially inhibit SARS-CoV-2 replication and attachment to host cell receptors. Conclusions These preliminary data propose NS as a potential phytotherapy candidate for COVID-19. Further preclinical experimental evidence is required followed by a phase 1 clinical trial. Keywords: SARS-CoV-2; COVID-19; Coronavirus; In-silico; Nigella sativa Running Title: Nigella sativa in COVID-19spa
dc.format.extent13 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherCurrent Therapeutic Researchspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCOVID-19spa
dc.subjectPotential phytotherapyspa
dc.titleNigella sativa l. as a potential phytotherapy for covid-19: A mini-review of in-silico studiesspa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAbierto (Texto Completo)spa
dc.identifier.doihttps://doi.org/10.1016/j.curtheres.2020.100602spa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record